Researchers at the LSU LCMC Health Cancer Center examined tumors from more than 250 Black and white women across Louisiana and uncovered key immune differences in patients with triple-negative breast cancer, one of the most aggressive forms of breast cancer.
FDA has approved rucaparib (Rubraca) for adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer previously treated with an androgen receptor-directed therapy.
